Christina T. Roupas

Cooley advised NETSTREIT on a $250 million sustainability-linked senior unsecured term loan facility agented by Truist Bank, as well as the amendment and extension of its existing $175 million senior unsecured term loan agented by Wells Fargo Bank. NETSTREIT is a real estate investment trust based in Dallas, Texas, that acquires single-tenant net lease retail properties across the US. Michael Tollini, Christina Roupas, Addison Pierce, Sai Yarramalla, Margaret Barreto and Leah Duncan led the Cooley team.

Cooley advised the underwriters in Vivid Seats’ $128 million follow-on offering. Vivid Seats is an online ticket marketplace connecting fans to live events and artists. As the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theaters and comedy, Vivid Seats operates in two segments – marketplace and resale. Lawyers Christina Roupas, Courtney Tygesson, Grady Chang, Sam Paullin, Leah Duncan and Adam Bloom led the Cooley team.

Cooley advised NETSTREIT Corporation’s $209 million forward sale of 10,350,000 shares of common stock at a public offering price of $20.20 per share. NETSTREIT is a real estate investment trust based in Dallas, Texas, that specializes in acquiring single-tenant net lease retail properties nationwide. Partners Christina T. Roupas, Courtney M.W. Tygesson and Mischi a Marca led the Cooley team.

Cooley advised NETSTREIT on its $230 million forward sale of 10,350,000 shares of common stock. NETSTREIT is a real estate investment trust based in Dallas, Texas, that specializes in acquiring single-tenant net lease retail properties across the US. Partners Christina Roupas, Courtney Tygesson and Mischi a Marca led the Cooley team.

Cooley advised the underwriters on DICE Therapeutics’ $234.6 million initial public offering of 13,800,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. BofA Securities, Inc., SVB Leerink LLC and Evercore Group L.L.C. acted as the lead book-running managers for the offering. DICE Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol “DICE,” is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Partners Charlie Kim, Christina Roupas, Kristin VanderPas and Courtney Tygesson led the Cooley team.